Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 1244 results for public health guidance

  1. Getting involved as someone with lived experience

    We want you to help NICE to develop our guidance for NHS and care services.

  2. Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]

    Awaiting development Reference number: GID-TA11308 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Palbociclib with anti-HER2 and endocrine therapies for maintenance treatment of hormone-receptor positive HER2-positive metastatic breast cancer [ID6251]

    Awaiting development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTG10875 Expected publication date:  10 March 2027

    HealthTech guidance
    In development

  5. How we develop NICE guidelines

    The guidance development timeline

  6. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.

    Technology appraisal guidance
    Published
    18 December 2019
    View recommendations

    Sections for TA615

  7. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016

  8. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  9. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  10. Tobacco: treating dependence (QS207)

    This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    15 December 2022
    View quality statements

    Sections for QS207

  11. Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

    This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    23 July 2015
    View quality statements

    Sections for QS96

  12. Technologies for the rapid diagnosis of endometriosis: early use assessment

    In development Reference number: GID-HTE10082 Expected publication date:  08 October 2026

    In development

  13. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    Awaiting development Reference number: GID-TA11624 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]

    In development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    In development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    In development